I don't believe the company could control what the European's did, but I suspect they'll agree to look at the OS data and pretty much ignore the rest. When we get the Journal I believe it will address why PFS didn't work in this trial and it won't work if pseudoprogression is found and can't be differentiated from progression easily. Putting patients through some painful procedure doesn't seem like the right thing to do.
Why? USA one is still a subset of the UK and Germany one; the latter is a more elaborated one but completely based on OS data. USA one is good for the upcoming publication which will talk about only these two endpoints time being it seems now which is really good, imo.
News 
Market Data 
Discover 
